samedan logo
 
 
spacer
home > pmps > spring 2003 > inkjet digital printing offers additional solutions in the battle against anticounterfeiting
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Inkjet Digital Printing Offers Additional Solutions in the Battle Against Anticounterfeiting

The Anti-Counterfeiting Group (ACG) defines counterfeiting as:

the deliberate attempt to deceive consumers by copying and marketing goods bearing well-known trade marks generally, together with packaging and product configuration, so that they look like they are made by a reputable manufacturer when they are, in fact, inferior copies.

The global counterfeiting market is immense and fast growing with losses to government, business, and citizens estimated at eight per cent of world trade according to the Counterfeiting Intelligence Bureau. At a recent ACG conference, the costs of counterfeiting to the UK were estimated at a staggering £9 billion and 4,100 job losses per annum. In 2001, this illicit industry cost the Exchequer over a billion pounds in taxes. The statistics are shocking and losses in the future are set to increase due to sophisticated replication technologies making counterfeiting a constant threat.

More far-reaching but less easily-defined losses are also possible through the stifling of innovation due to a disinclination to invest millions of pounds in product development only to have the products immediately counterfeited. Despite the growing range of security solutions currently in existence, losses as a result of counterfeiting are still growing faster than the total security solutions and security technologies market - about 15 per cent per annum.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jan Van Laethem, Product Manager of Security Systems at dotrix NV

Jan Van Laethem is Manager of Security Systems at dotrix nv, a Belgian manufacturer of inkjet digital presses designed for industrial applications. He is responsible for security and personalisation applications.

Prior to dotrix's creation in December 2002, following a management buyout by the former Barco Graphics Industrial Printing Business Unit, Jan spent 13 years at Barco Graphics. There he worked in software application development for CAD systems for the packaging design market for a few years before becoming involved in the development of a specific CAD system for the ceramics design market. In 1993, he joined Barco's Security Systems Group, where he became group responsible in 1998. Jan Van Laethem holds a degree in Electronic Engineering.

spacer
Jan Van Laethem
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement